Gladstone Investment (GAIN) Q4 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants David Gladstone - Founder, Chairman & CEOMichael Licalsi - General Counsel & SecretaryDavid Dullum - PresidentTaylor Ritchie - CFOMickey Schleien - MD - Equity ResearchErik Zwick - Managing Director, Equity Research Operator and welcome to Gladstone Investment Corporation Fourth Quarter and Year End Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session w ...

Core Viewpoint - Bekaert is navigating challenging market conditions due to tariffs and trade tensions, successfully passing on costs to customers while maintaining a strong balance sheet and stable sales expectations for 2025 [1][5]. Financial Highlights - Q1 2025 consolidated sales were €991 million, a decrease of 3% compared to Q1 2024, driven by a 1% decline in like-for-like volumes (€12 million), a 1% reduction from price-mix (€11 million), and a 2% pricing impact from lower input costs (€23 million) [4]. - Sales from joint ventures (non-consolidated) amounted to €214 million, down 2% from Q1 2024 [4]. - A proposed dividend of €1.90 per share at the AGM and an ongoing two-year €200 million share buyback program, with approximately €50 million purchased to date [4]. Operational and Strategic Highlights - The company has been able to mitigate tariff impacts through local sourcing and production, with minimal financial impact from tariffs to date [1][5]. - The Rubber Reinforcement segment showed strong performance in China, offsetting volume decreases in Europe and North America, while the Steel Wire Solutions segment reported solid sales performance [4]. - Specialty Businesses faced project delays in flooring in North America, but adoption is accelerating in growth markets [4]. Tariff Impacts - The introduction of tariffs has created significant uncertainty, leading to delayed orders and investment decisions from customers, particularly in the construction segment [2]. - The long-term effects of tariffs on end market demand and trade flows remain uncertain and could be material [2]. Outlook - The difficult market conditions from the second half of 2024 are expected to persist into Q1 2025, with ongoing uncertainty around tariffs and the global macroeconomic outlook [3]. - The company anticipates stable sales and EBIT margins for the full year 2025 compared to 2024, with a more balanced performance expected between the first and second halves of the year [5].

Revvity (RVTY) 2025 Conference Summary Company Overview - **Company**: Revvity (RVTY) - **Date**: May 13, 2025 - **Industry**: Life Sciences Tools and Diagnostics Key Points 1. Q1 Performance and Guidance - The first quarter showed solid performance despite a different macro environment than initially assumed for 2025 guidance [4][5] - The diagnostics and software businesses performed exceptionally well, contributing to the overall strength of the portfolio [4][5] - The company maintained full-year guidance despite a weaker macro backdrop due to prudent initial guidance [5] 2. Tariff Impact and Mitigation Strategies - Gross tariff headwinds were estimated at $135 million, with a net impact of approximately $0.12 on EPS after operational mitigation [6][12] - The majority of tariff impacts are expected in the second quarter, with operational mitigation strategies being implemented [6][12] - The company has a dual manufacturing strategy to enhance supply chain resiliency, including a GMP facility in San Diego and another outside the US [10] 3. Academic and Government Market Exposure - Academic and government customers account for 12% of global revenue, with over 5% in the US [21] - There is cautiousness in these segments due to uncertainties around indirect expense reimbursements and NIH funding levels [22][24] 4. Pharma and Biotech Market Trends - The pharma and biotech sectors showed positive growth in Q1, but there is uncertainty due to macroeconomic factors and tariffs [28] - Instrumentation sales are expected to face continued pressure, particularly from mid and large-sized pharma customers [29][30] 5. Geographic Performance - China represents 16% of total revenue, with diagnostics showing high single-digit growth while life sciences experienced a slight decline [34] - The company anticipates continued choppiness in the China life sciences market but modest growth in diagnostics [34][35] 6. Software Business Strength - The software business is highlighted as a major area of strength, with new product launches and a focus on large molecule capabilities [48][49] - The company is expanding into new customer groups and markets, such as material science, which has shown good traction [49] 7. Margin Expectations and Cost Management - The company expects balanced margin expectations for the year, with temporary belt-tightening measures in place to mitigate tariff impacts [50][51] - There are no plans for additional structural cost reductions, but ongoing monitoring will occur [51] 8. Capital Allocation and M&A Strategy - Revvity has adopted a balanced approach to capital deployment, including share buybacks and selective M&A opportunities [55][56] - The company is cautious about M&A in the current market, noting that private companies are not in a rush to sell despite lower valuations [57][59] 9. Underappreciated Aspects of Revvity - The company’s differentiated portfolio and execution capabilities are not fully recognized in the market [61][62] - There is potential for margin expansion that has yet to be demonstrated due to current market pressures [62][63] 10. Future Outlook - The company remains optimistic about its long-term growth potential, particularly in the reagents business and software capabilities [41][48] - Continued execution and clarity in macroeconomic conditions are essential for demonstrating the company's margin expansion opportunities [63] This summary encapsulates the key insights and data points from the Revvity conference, providing a comprehensive overview of the company's current performance, challenges, and strategic outlook.

金十数据整理：美国4月CPI报告看点一览 1. 通胀率降至近年新低——整体CPI年率降至2.3%，核心CPI年率持平于2.8%。两项指标均创下2021年 春季通胀全面爆发以来的最低增速。 5. 市场对数据反应温和——CPI数据公布后，现货黄金小幅走高后回落，美债延续涨势但波幅有限；美 股三大股指开盘涨跌不一，此后持续震荡走高，纳指涨逾1%。 2. 月率涨幅低于预期——整体CPI月率及核心CPI月率均上涨0.2%，低于市场预期的0.3%。与往常一 样，居住成本涨幅占整体月率的一半以上；家居用品、医疗护理及车险价格则推动了核心月率上涨。 3. 关税影响初现但尚不明显——家居用品和音响设备价格飙升8.8%（创下有史以来最大单月涨幅）或 初步反映关税影响，但经济学家表示全面影响仍待观察，后续数据或能更明显地反映出关税影响。 4. 食品与能源价格走势分化——美国4月杂货价格下降0.4%，其中鸡蛋价格暴跌12.7%，创1984年以来 最大跌幅。这印证了特朗普的部分说法，但能源成本上涨0.7%与其主张相悖。经季调后汽油价格微 降，而天然气价格大幅跳涨。 ...

Hydrofarm (HYFM) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Anna Kate Heller - Senior Vice President, Investor RelationsB. John Lindeman - CEOKevin O’Brien - CFO Conference Call Participants Dmitry Silversteyn - Senior Research Analyst Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the HydroPharm Holdings Group First Quarter twenty five Earnings Conference Call. At this time, all participants have been placed in a listen only mode and the lines wi ...

沙特阿美高管：尽管面临关税影响和宏观经济不确定性，预计第二季度将实现稳健增长。 ...

证券研究报告 宏观 4 月全球 PMI:关税拖累开始显现 华泰研究 2025 年 5 月 09 日│中国内地 动态点评 研究员 易峘 evayi@htsc.com SAC No. S0570520100005 SFC No. AMH263 +(852) 3658 6000 研究员 胡李鹏，PhD SAC No. S0570525010001 hulipeng@htsc.com +(86) 10 6321 1166 研究员 陈玮 SAC No. S0570524030003 SFC No. BVH374 chenwei023580@htsc.com +(86) 10 6321 1166 联系人 赵文瑄 SAC No. S0570124030017 zhaowenxuan@htsc.com +(86) 10 6321 1166 图说全球 PMI | 2025 年 4 月 本系列为华泰宏观出品、全球 PMI 月度追踪系列的第二十二期。4 月全球制 造业 PMI 显示关税的影响开始显现，制造业 PMI 回落至荣枯线以下，部分 新兴市场经济体回落较为明显；制造业新订单和新出口订单分项明显回落； 价格指标维持高位，产成品 ...

大行观点 智通财经APP获悉，沃尔玛(WMT.US)将于5月15日（周四）美股盘前公布2026财年第一季度财报。这份 报告将被零售业视为衡量美国消费者健康状况和整体零售趋势的关键指标，同时也是观测企业是否会将 关税成本直接转嫁给消费者的重要风向标。分析师预计沃尔玛将披露1645亿美元营收和每股0.58美元的 收益，符合公司此前给出的0.57-0.58美元每股收益指引。 在消费者因担忧未来关税相关价格上涨而囤积家居用品的趋势下，美国同店销售额预计增长3.6%。沃 尔玛的业绩指引被认为具有足够包容性，能够涵盖更广泛的结果。 沃尔玛管理层此前预测，在整合VIZIO收购业务并应对不利品类组合的情况下，全年净销售额将增长 3%至4%，调整后营业利润增长3.5%至5.5%。 投资者将密切关注沃尔玛在持续宏观经济挑战中保持发展势头的能 力，这些挑战包括通胀、消费者支 出模式转变以及新颁布关税的影响。 财报电话会议的焦点将包括沃尔玛的广告业务、电子商务表现、市场份额增长、库存管理、供应链和采 购战略，以及在经济和贸易战不确定性下对消费者行为的评论。 分析师认为沃尔玛此次财报比往常更具分量，因为市场正在深入探讨通过抑制涨价来扩 ...

上周国际市场风云变幻，汇市波动有所加剧，贸易谈判持续受到关注。美股小幅走低，道指周跌 0.16%，纳指周跌0.27%，标普500指数周跌0.47%。欧洲三大股指涨跌互现，英国富时100指数周跌 0.48%，德国DAX 30指数周涨1.79%，法国CAC 40指数周跌0.34% 本周看点颇多，在美国和英国宣布贸易协议后，投资者焦点将继续聚焦美国进一步宣布贸易协议的前景 上。美国将公布通胀、零售和消费者信心的重要指标，可能进一步反映关税的影响。欧佩克月报将发 布，有关供需前景的判断将吸引市场目光。阿里巴巴、京东等中概股财报将亮相。 关税影响或将显现 美联储上周按兵不动，由于特朗普的贸易政策，失业率和通货膨胀率都有上升风险，目前还不急于降 息。 数据方面，美国4月通胀数据将公布，这被视为美联储未来政策决定的重要参考。目前没有迹象表明通 货膨胀正在加速，因为3月份CPI和PCE指标都有所下降。然而，随着4月对等关税决定公布，通货膨胀 的降温可能是暂时的。尽管高于10%的普遍税率的更高征税被推迟了90天，其他一些豁免也被宣布，但 预计大多数进口商品的价格至少会上涨一定幅度。 荷兰国际集团（ING）经济学家奈特利（Jam ...

现货黄金本周先涨后跌走势，收于3326.56美元/盎司。周初，受美元走软和避险需求推动，以及得益于亚洲买家节后重返黄金市场，现货黄金日内再现近 100美元的涨幅。周三开始，因市场对贸易谈判持乐观态度，加上美元走强，现货黄金转为下跌，但并未全部抹去此前涨幅，本周仍录得收涨。 四小时级别上，金价仍处于三角收敛形态的整理区间，尽管周五早盘出现短暂下轨刺破，但该支撑位的有效性仍需进一步确认。预计下周金价将在3378- 3274区间维持震荡，投资者可密切关注区间破位信号，待趋势明朗后再调整交易策略。值得警惕的是，当前消息面波动频繁，黄金市场高基数背景下，单日 百点波动已成常态，建议投资者务必做好仓位风险管理。 黄金走势分析：本周黄金市场以一根标志性的"倒锤头"阳线收官，K线形态尽显多空博弈的激烈交锋。周初，受消息面避险情绪驱动，金价一度强势上扬， 但相较于此前关税战助推金价触及3500历史高位的盛况，本次市场反应明显钝化，涨势在3439处戛然而止。随着后半周美联储利率决议按兵不动的靴子落 地，金价开启剧烈回调模式，短短两日累计下挫170点，最终收盘守住3300关键关口。结合此前的黄昏之星K线组合与本周倒锤头形态，秦氏金 ...